Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide typically begins reducing appetite within the first one to two weeks of starting, though meaningful weight loss usually becomes visible after four to eight weeks. Most people in clinical trials saw around 5% body-weight reduction within the first three months, with results continuing to build over 72 weeks. These are prescription-only medicines; a GPhC-registered prescriber assesses your suitability before any treatment begins. The speed at which tirzepatide works for weight loss varies by individual, starting dose, and how the body responds — this page walks through what the evidence actually shows, month by month.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first injection is 2.5 mg, and its job is to settle your system rather than drive weight loss. That said, many people notice a meaningful drop in appetite and food noise within the first seven to fourteen days. Gastric emptying slows, fullness arrives sooner at meals, and the urge to snack between them often fades. For some this shift is subtle; for others it feels almost immediate.
Weight on the scales may not move much in weeks one and two, and that's normal. The body is adjusting to a new hormonal signal, not undergoing a dramatic metabolic event. If you started your first pen mid-month, say the week before payday or just before a bank holiday, the practical tip is to track how you feel rather than what the scales read for those early weeks, the trend matters more than any single weigh-in.
Side effects, mainly nausea, can also feel most noticeable at the start or after each dose increase. These tend to settle within a week or two. The full tirzepatide overview at nume covers what to expect from each phase of treatment. The more detailed breakdown of Mounjaro's timeline addresses exactly when these early sensations tend to peak and ease.
By weeks four to eight (typically after the first or second dose increase) weight loss becomes measurable for most people. A 2–4% reduction in body weight within this window is a realistic, evidence-based expectation. By the end of the third month, many participants in the SURMOUNT-1 trial had achieved around 5% weight reduction, and that figure kept climbing.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks. At the 15 mg dose, average body-weight reduction reached approximately 20–21%. Crucially, that wasn't achieved in a rush: the trial design mirrors the real-world titration schedule, with the dose increasing gradually every four weeks. The largest monthly drops in weight tended to occur in the middle months of treatment, once people reached a higher maintenance dose and their body had adapted to it.
How quickly tirzepatide works for weight loss also depends on how closely the lifestyle changes (lower-calorie eating and more movement) are integrated alongside it. The medicine reduces appetite; the choices that follow still matter. If you want a focused look at how quickly you lose weight on tirzepatide, that page sets out what the evidence shows at each stage of the journey. This page on Mounjaro's weight-loss pace sets out the figures by phase.
Yes, and this is one of the most clinically important things to understand about tirzepatide's timeline. The titration schedule (2.5 mg, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each typically held for around four weeks) isn't just about tolerability. Each step tends to bring a fresh period of more noticeable appetite reduction, followed by weight loss that reflects it.
This means results often accelerate in waves rather than as a straight line downward. Some weeks the scales barely move; the following fortnight they might drop more sharply. People who are partway through titration often ask whether tirzepatide is still working. Generally it is, the body needs time to respond to each new dose level before the effect becomes visible on the scales.
NICE's appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. That guidance exists precisely because the medicine takes time to show its full effect, six months, not six weeks, is the relevant timeframe for a definitive assessment. For a sharper comparison of timelines, the page on how fast tirzepatide works sits alongside this one.
Starting body weight, metabolic factors, and how well GI side effects are managed all influence the pace of results. Someone with a BMI of 38 and a very high starting weight may see a larger absolute number on the scales earlier, even if the percentage is similar to someone lighter. Conversely, people whose nausea leads them to skip doses or reduce their food intake drastically may see quick early results that don't reflect sustainable progress.
Concurrent medicines can also play a role; a prescriber reviews the full picture during assessment. The consultation at our weight-loss treatment page is the right place to explore whether tirzepatide fits your circumstances, a real clinician reads your answers and considers exactly these factors before any prescription is issued.
The NHS's information on tirzepatide provides patient-level detail on how the medicine works and what to monitor during treatment. And if the question is less about speed and more about the shape of the overall journey, this page on how long tirzepatide takes to work covers the longer arc of treatment in detail. Our clinical team is available for aftercare questions seven days a week once treatment is under way.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.